Handok Pharmaceuticals’ Chairman/CEO Young-Jin Kim and Fresenius Kabi Korea’s CEO/President Yoon Gi Hong signed a contract for the domestic marketing and sale of four Fresenius Kabi generic oncology products that already have approval for marketing. Handok Pharmaceuticals plans to set up a dedicated oncology department and expand its oncology portfolio by introducing additional products developed by Fresenius Kabi.